Hai Ying Hang

Title: The Innovations of Hai Ying Hang

Introduction

Hai Ying Hang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly through his innovative work on interleukin-21 proteins. His research focuses on enhancing immune responses and developing potential anti-tumor therapies.

Latest Patents

Hai Ying Hang holds a patent for an interleukin-21 protein (IL21) mutant and its encoding nucleic acid. This invention involves a mutant form of IL21, where ILE at position 16 and SER at position 70 of the amino acid sequence are both mutated into CYS. This modification allows for the formation of a disulfide bond between the two mutated CYSs. The invention also encompasses a fusion protein containing the IL21 mutant protein, which can be utilized in the preparation of medicines aimed at regulating or activating immunity, as well as anti-tumor treatments. Furthermore, the IL21 mutant and its fusion protein are designed to promote the differentiation and proliferation of B cells, T cells, and NK cells.

Career Highlights

Hai Ying Hang is associated with Hyquo Molecule (Beijing) Technology Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, contributing to innovative solutions for medical challenges.

Collaborations

He collaborates with notable colleagues, including Xin Zhang and Yun Zhao, who share his commitment to advancing scientific knowledge and developing new therapeutic approaches.

Conclusion

Hai Ying Hang's contributions to the field of biotechnology, particularly through his patented innovations, highlight his role as a leading inventor in the industry. His work promises to impact the future of medicine significantly.